Publication:
Randomized double-blind placebo-controlled phase 2 study of bemarituzumab combined with modified FOLFOX6 (mFOLFOX6) in first-line (1L) treatment of advanced gastric/gastroesophageal junction adenocarcinoma (FIGHT).

Placeholder

Organizational Units

Program

Authors

Wainberg, Zev A.
Enzinger, Peter C.
Kang, Yoon-Koo
Yamaguchi, Kensei
Qin Shukui, Qin Shukui
Lee, Keun-Wook
Oh, Sang Cheul
Li Jin, Li Jin
TÜRK, HACI MEHMET
Teixeira, Alexandra Carolina

Advisor

Language

Publisher

Journal Title

Journal ISSN

Volume Title

Abstract

Description

Source:

Keywords:

Keywords

Citation

Wainberg Z. A. , Enzinger P. C. , Kang Y., Yamaguchi K., Qin Shukui Q. S. , Lee K., Oh S. C. , Li Jin L. J. , TÜRK H. M. , Teixeira A. C. , et al., -Randomized double-blind placebo-controlled phase 2 study of bemarituzumab combined with modified FOLFOX6 (mFOLFOX6) in first-line (1L) treatment of advanced gastric/gastroesophageal junction adenocarcinoma (FIGHT).-, JOURNAL OF CLINICAL ONCOLOGY, cilt.39, sa.3, 2021

Endorsement

Review

Supplemented By

Referenced By

0

Views

0

Downloads

View PlumX Details


Sustainable Development Goals